Hodgkin's disease and the malignant lymphomas

Area of Science:

• Oncology
• Hematology
• Pathology

Background:

• Subcutaneous swelling, often an enlarged lymph node, warrants investigation for neoplastic conditions.
• Historically, Hodgkin's disease was debated as inflammatory versus malignant, with early links to tuberculosis.
• Consensus now classifies Hodgkin's disease as a neoplastic process, distinct from other lymphomas.

Purpose of the Study:

• To review the historical progression and current understanding of Hodgkin's disease diagnosis and management.
• To highlight key milestones in treatment, including radiotherapy and combination chemotherapy.
• To emphasize the need for multidisciplinary approaches in managing resistant or relapsing cases.

Main Methods:

• Historical review of diagnostic criteria and treatment evolution for Hodgkin's disease.
• Discussion of therapeutic modalities: radiotherapy, combination chemotherapy, and investigational programs.
• Exploration of supportive care strategies like cytokines and bone marrow transplantation for refractory disease.

Main Results:

• Accurate diagnosis, precise staging, and appropriate treatment selection are cornerstones of successful Hodgkin's disease management.
• Radiotherapy and combination chemotherapy have significantly improved cure rates.
• Multidisciplinary approaches and clinical trials are crucial for patients with resistant or relapsing disease.

Conclusions:

• Hodgkin's disease management has evolved significantly, with established curative treatments.
• Challenges remain in treating refractory and relapsing cases, underscoring the need for advanced therapeutic strategies.
• Future research should focus on optimizing treatments within well-structured clinical trials, balancing efficacy and safety.